For what its worth.
Here is the opinion, offered this week by a professional biotech analyst on NEU.
NEU's lead candidate NNZ2566 is a glycine-proline-glutamate (GPE) which is an N-terminal tripetide endogenously cleaved from insulin like growth factors (IGF1).
Numerous attempts have been made by large pharmas to develop drugs targeting IGF1 but all have failed. There is not much human data to date that indicates the success of NEU's programs.
nnz-2566 trial updates, page-13
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.52 |
Change
0.660(3.32%) |
Mkt cap ! $2.622B | |||
| Open | High | Low | Value | Volume |
| $20.00 | $20.66 | $19.94 | $6.431M | 315.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1024 | $20.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.53 | 285 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |